CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Palatin
Technologies, Inc. (Amex: PTN) will discuss the fourth quarter and year end
financial results for the fiscal year ended June 30, 2008 and provide an
update on corporate developments during a conference call and webcast on
September 30, 2008 at 11:15 a.m. ET.
Conference Call and Webcast Access Information
-- Q4-Fiscal Year 2008 Conference September 30, 2008 at
Call - Live 11:15 a.m. ET
Domestic Dial-In Number 1-888-263-2958
International Dial-In Number 1-913-312-6664
-- Q4-Fiscal Year 2008 Conference September 30 - October 7, 2008
Call - Replay
Domestic Dial-In Number 1-888-203-1112
International Dial-In Number 1-719-457-0820
Replay Passcode: 6671824
-- Webcast Live and Replay Access http://www.palatin.com
The webcast and replay can be accessed by logging on to the "Investor Center-Webcasts" section of Palatin's website at http://www.palatin.com.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of proprietary peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.
|SOURCE Palatin Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved